Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Matthew Charles Evans"'
Autor:
Bethany A. Jackson, Matthew Charles Evans, Gareth AstraZeneca R D Charnwood Ensor, Adam Clarke, Chris D. Parsons, Mairi M. Littleson, Mark Dow, Danny H. Legg, Thomas O. Ronson, Adam Herring, David J. Klauber, Štefan Moravčík, Rebecca E. Meadows, Andrew D. Campbell, Jackson Lucinda Victoria, Kevin William Leslie, Staffan Karlsson
Publikováno v:
Organic Process Research & Development. 23:1407-1419
The AstraZeneca approach to synthetic Route Design is exemplified through our AZD4635 chemical development program. The identification of possible new route concepts is presented, as well as their ...
Autor:
Sahar McKeever-Abbas, Robert L. Woodward, David Whittaker, Janette H. Cherryman, Alex Crampton, Edward G. B. Eden-Rump, Martin F. Jones, Matthew Charles Evans, Ian W. Ashworth, Rebecca E. Meadows, Phillip A. Inglesby, Andrew D. Campbell, Kathryn Skilling, Jemma Clark
Publikováno v:
Organic Process Research & Development. 22:1801-1808
We developed a scalable Suzuki process for the synthesis of lanabecestat (+)-camsylate, an active pharmaceutical ingredient that was recently investigated in a Phase III clinical program for the treatment of early Alzheimer’s disease. The evolution
Autor:
Kirsty Millard, Oliver R. Cunningham, Matthew Charles Evans, Brian Whitlock, Raquel Rozada-Sanchez, Paul Siedlecki, William R. F. Goundry, Yvonne Sawyer, Kay Alison Boardman, Martin F. Jones
Publikováno v:
Organic Process Research & Development. 21:336-345
Recently, the aminoquinazoline motif has been highly prevalent in anticancer pharmaceutical compounds. Synthetic methods are required to make this structure on a multikilo scale and in high purity. The initial route to aminoquinazoline AZD8931 suffer
Autor:
Melanie Ronsheim, Shao Hong Zhou, Graham Richard Lawton, Alistair Boyd, Simon R. Linke, Yuriy B. Kalyan, Matthew Charles Evans, Rebecca Murphy, David Milne, Michael David Golden, Matthew Ball, Saibaba Racha, Gareth AstraZeneca R D Charnwood Ensor, Alex Telford
Publikováno v:
Organic Process Research & Development. 20:1799-1805
Process development work to provide an efficient, robust, and cost-effective manufacturing route to avibactam, a β-lactamase inhibitor is presented herewith. Aspects of this optimization work include the counterintuitive introduction of a protecting